Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
Quick facts
Marketed products
- Atorvastatin-esomeprazole · Cardiovascular
This combination drug lowers cholesterol by inhibiting HMG-CoA reductase (atorvastatin) while reducing gastric acid secretion by blocking the proton pump (esomeprazole). - Atorvastatin-omeprazole · Cardiovascular
This is a fixed-dose combination of atorvastatin (a statin that lowers cholesterol) and omeprazole (a proton pump inhibitor that reduces stomach acid). - Atorvastatin-pantoprazole
- Atorvastatin-ranitidine
- Rivaroxaban, dabigatran, apixaban, or edoxaban · Cardiovascular
These are direct oral anticoagulants (DOACs) that inhibit specific clotting factors to prevent blood clot formation. - Rosuvastatin-esomeprazole
- Rosuvastatin-omeprazole · Cardiovascular
This combination drug reduces cholesterol via HMG-CoA reductase inhibition (rosuvastatin) while simultaneously reducing gastric acid secretion (omeprazole) to protect the gastrointestinal tract. - Rosuvastatin-pantoprazole · Cardiovascular
This combination drug lowers cholesterol via HMG-CoA reductase inhibition (rosuvastatin) while reducing gastric acid secretion via proton pump inhibition (pantoprazole). - Rosuvastatin-ranitidine · Cardiovascular
This is a fixed-dose combination of rosuvastatin (a statin that lowers cholesterol) and ranitidine (an H2-receptor antagonist that reduces stomach acid).
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec portfolio CI brief
- Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec pipeline updates RSS
Frequently asked questions about Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec
What are Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec's marketed drugs?
Top marketed products include Atorvastatin-esomeprazole, Atorvastatin-omeprazole, Atorvastatin-pantoprazole, Atorvastatin-ranitidine, Rivaroxaban, dabigatran, apixaban, or edoxaban, Rosuvastatin-esomeprazole.
Related
- Atorvastatin-esomeprazole · Cardiovascular
- Atorvastatin-omeprazole · Cardiovascular
- Atorvastatin-pantoprazole
- Atorvastatin-ranitidine
- Rivaroxaban, dabigatran, apixaban, or edoxaban · Cardiovascular
- Sector hub: All tracked pharma companies